NCT06161454 - Xofluza-Wearables Feasibility-Study | Biotech Hunter

Enrollment

498

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Infection, CoronavirusInfectionsInfluenzaTransplantInfection Viral

Interventions

DRUG

Baloxavir Marboxil

"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 20-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"

Trial Locations (1)

19014

Children's Hospital of Philadelphia, Philadelphia